Abstract
A new macrolide antibacterial agent, a so-called azalide derivative, azithromycin (AZM), was used in 5 patients with respiratory infection. Its clinical efficacy, bacteriological effect, and safety were examined in 4 patients with acute bronchitis (excluding 1 who dropped out after initiation of the study). The result was assessed to be good in all 4 cases. Among 3 cases with established pathogens, the bacterial result was ‘eradicated’ in 2 cases and ‘decreased’ or ‘partially eradicated’ in case. No adverse reactions thought to be due to AZM were noted. As abnormal changes in laboratory values, slightly elevated GOT and GPT
